Multimodal Treatment of Advanced Testicular Tumor with Radical Reductive Surgery and Multisequential Chemotherapy with CIS Platinum, Bleomycin, Vinblastine, Vincristine and Actinomycin D

Abstract

Advanced testicular tumors in 34 patients were treated by combination chemotherapy with bleomycin, vinblastine, vincristine, cis platinum and actinomycin D. The therapy was divided into 3 phases: induction, consolidation and maintenance. Induction lasted 4 wk and consisted of 420 mg bleomycin, 0.2 mg/kg vinblastine, 4 mg/kg cis platinum and 20 mg prednisone daily. Consolidation lasted 6 wk and consisted of 5 mg actinomycin D, 6 mg vincristine and 6 mg/kg cis platinum. Maintenance therapy was achieved with 2.5 mg actinomycin D every 6 wk and 1 mg/kg cis platinum every 3 wk. A tumor reductive operation was done before induction of chemotherapy in 13 patients and after induction of chemotherapy in 12 patients. Nine patients were treated with chemotherapy alone. Three patients with brain metastases received concomitant radiotherapy to the brain (3000 rad). A previous operation and chemotherapy had failed in 11 patients and previous radiotherapy had failed in 1 patient. All patients treated had at least 1 objective response (34 of 34 or 100%). Partial clinical remission was achieved in 7 of 34 patients (21%). A complete clinical remission was observed in 27 of 34 patients (79%) and of this group, 6 had a relapse. At present, 22 of 34 patients are free of disease from 4-24 mo., with an average of 13 mo. (65%). The toxicity consisted of nausea, vomiting, mucositis, alopecia, mild leukopenia and tinnitus. This approach seemed to be effective in producing long clinical remissions in the majority of patients with advanced disease.